Asian Journal of Pharmaceutical Analysis

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Design and Validation of Dissolution Profile of Rivaroxaban by Using RP-HPLC Method in Dosage Form


Affiliations
1 Shree Dhanvantary Pharmacy College, Department of Quality assurance, Kim, Surat, India
     

   Subscribe/Renew Journal


Rivaroxaban, anti-coagulant is a novel drug for the prevention of venous thromboembolism (VTE) in patients who have undergone elective total hip replacement or total knee replacement surgery and no dissolution study for its estimation has been reported yet. The aim of this work was to develop and validate a dissolution profile for Rivaroxaban in a tablet dosage form using RP-HPLC method. The conditions established for dissolution were: 900 mL of acetate buffer pH=4.5 + 0.2 % sodium lauryl sulphate (SLS) as dissolution medium, using a paddle type dissolution apparatus at a stirring rate of 75 rpm which was able to give % drug release of 98.86% . The drug release was evaluated by RP-HPLC method at 250 nm and a good linearity was observed in the concentration range of 20-60 μg/mL with correlation coefficient of 0.9989. The percentage recovery of Rivaroxaban was found to be 99.63 and % CV (0.22 %; n=6) indicated a good precision of the analytical method.. Robustness of the method was performed by using different rotation speeds and Temperatures. The validation parameters included linearity, accuracy, precision and robustness. Analytical method validation was found to be within the acceptance criteria of the guidelines of ICH Q2 R1, FDA and FIP. The proposed method can be applied for routine quality control analysis of Rivaroxaban

Keywords

Rivaroxaban, Validation, Dissolution Apparatus,RP-HPLC Method, 250 nm
Subscription Login to verify subscription
User
Notifications
Font Size


  • "Xarelto: Summary of Product Characteristics". Bayer Schering Pharma AG. 2008.

  • "FDA Approves XARELTO (Rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery". Janssen Pharmaceutica.

  • "Bayer's Xarelto Approved in Canada" (Press release). Bayer.

  • "Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU". Bayer.

  • ”Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)- 2- oxo-3- [4-(3- oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5- yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor"., Roehrig S, Straub A, Pohlmann J, et al, Journal of Medicinal Chemistry 48 (19): 5900–8.

  • Center for drug evaluation and research and Clinical pharmacology and biopharmaceutics review(s) of Rivaroxaban

  • P.V.V. Satyanarayana, Alavala Siva Madhavi, Department of Chemistry. New Spectrophotometric methods for the quantitative estimation of Rivaroxaban in formulations, International Journal of Research and Reviews in Pharmacy and Applied science, 611-620.

  • Job Harenberg, Roland Kramer, Christina Giese, Svetlana Marx, Christel Weiss, and Martin Wehling. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability, Journal of Thrombosis and Thrombolysis, J Thromb Thrombolysis.; 32(3): 267–271, October 2011.

  • P.V.V Satyanarayana and Alavala Siva Madhavi. RP-HPLC method development and validation for the analysis of rivaroxaban in p

  • harmaceutical dosage forms, 2 (1), 226-231,2012.

  • Rohde G., Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry in Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 872(1-2):43-50, 2008.

  • Shah VP, Lesko LJ, Fan, Fleischer, J, N, J. Handerson, Malinowski, H, Makary, M, Ouderkirk, L, Roy, S, Sathe, P, Singh, GJP, Tillman, L, Tsong Y, Williams, RL., Dissolution Technol, 4(1997).

  • Moore, JW, Flanner, HH, Pharm Technol, 20(1996).

  • Khan, KA, J Pharm Pharmacol, 28(1975). 27. Noory C, Tran N, Ouderkirk L, Shah V, Dissolution Technol, 7(2000).

  • Q2R1 ICH guidelines for analytical method development. Available at: http://www.ich.org/fileadmin/Public_Web_Site /ICH_Products/ Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf 15 FIP guidelines for dissolution testing of solid oral products available at: http://www.fip.org /www /uploads/database_file.php?id=260 &table_id= 16. The United States Pharmacopoeia (2007) 31st Ed., Unites States Pharmacopoeial Convention, Rokville


Abstract Views: 2549

PDF Views: 3




  • Design and Validation of Dissolution Profile of Rivaroxaban by Using RP-HPLC Method in Dosage Form

Abstract Views: 2549  |  PDF Views: 3

Authors

Pinaz A. Kasad
Shree Dhanvantary Pharmacy College, Department of Quality assurance, Kim, Surat, India
K. S. Muralikrishna
Shree Dhanvantary Pharmacy College, Department of Quality assurance, Kim, Surat, India

Abstract


Rivaroxaban, anti-coagulant is a novel drug for the prevention of venous thromboembolism (VTE) in patients who have undergone elective total hip replacement or total knee replacement surgery and no dissolution study for its estimation has been reported yet. The aim of this work was to develop and validate a dissolution profile for Rivaroxaban in a tablet dosage form using RP-HPLC method. The conditions established for dissolution were: 900 mL of acetate buffer pH=4.5 + 0.2 % sodium lauryl sulphate (SLS) as dissolution medium, using a paddle type dissolution apparatus at a stirring rate of 75 rpm which was able to give % drug release of 98.86% . The drug release was evaluated by RP-HPLC method at 250 nm and a good linearity was observed in the concentration range of 20-60 μg/mL with correlation coefficient of 0.9989. The percentage recovery of Rivaroxaban was found to be 99.63 and % CV (0.22 %; n=6) indicated a good precision of the analytical method.. Robustness of the method was performed by using different rotation speeds and Temperatures. The validation parameters included linearity, accuracy, precision and robustness. Analytical method validation was found to be within the acceptance criteria of the guidelines of ICH Q2 R1, FDA and FIP. The proposed method can be applied for routine quality control analysis of Rivaroxaban

Keywords


Rivaroxaban, Validation, Dissolution Apparatus,RP-HPLC Method, 250 nm

References